Kinaset Therapeutics secured $103 million in a Series B round to progress its inhaled candidate for asthma toward late-stage testing. The financing comes five years after the company’s initial emergence with seed capital and reflects investor confidence in inhaled modalities for respiratory diseases. Kinaset will apply proceeds to clinical development and manufacturing scale-up for its inhaled program. Inhaled delivery aims to concentrate drug exposure in the lung while limiting systemic effects — a strategy that matters for safety in chronic airway diseases.